Target lysis by patients with NK-LDGL. (A) Direct killing of K562 cells as targets. To determine whether the cells from patients with NK-LDGL have NK lytic function, we performed standard ⁵¹Cr-release assays. The graphic representation of the percent specific lysis at a 50:1 effector-to-target ratio from normal PBMCs (NLPBMC), enriched NK cells (NLNK), and PBMCs from patients with NK-LDGL. (B) Redirected cytolysis using the FcR⁺ P815 tumor cell line as a target. PBMCs from patients with NK-LDGL and enriched NK cells from healthy individuals were compared using medium (Media), IgG (control antibody), anti-CD94 (coreceptor for some activating and inhibitory NKG2), anti-CD16, anti-CD158a (KIR2DS1, KIR2DS2), anti-CD158b (KIR2DL2, KIR2DL3, and KIR2DS2), anti-NKB1 (KIR3DL1), anti-NKG2A(inhibitory NKG2), and anti-NKG2D (activating NKG2) antibodies. The graphs represent the average of triplicate samples; standard deviation is indicated by the error bars.